99mTc-Pyrophosphate Shortage Continues

In late 2024, ASNC reported on difficulties with the 99mTc-pyrophosphate supply that were caused by a raw material shortage. Tc-99m pyrophosphate remains on the Food and Drug Administration’s Drug Shortage List. Both manufacturers, Curium and Sun Pharma, have been affected, and neither has provided an estimated shortage duration. Sun Pharma’s last statement, on Feb. 6, confirmed its inability to forecast a resupply date.

Some labs have changed their cardiac amyloid radionuclide bone imaging agent to 99mTc-hydroxymethylene diphosphonate (HMDP or HDP). The ASNC information statement Radiopharmaceutical Supply Disruptions and the Use of 99mTc-Hydroxymethylene Diphosphonate as an Alternative to 99mTc-Pyrophosphate for the Diagnosis of Transthyretin Cardiac Amyloidosis provides guidance for making this switch.

ASNC will continue tracking this situation. Stay tuned for updates. Please send your questions to info@ASNC.org.

Best Practices Webinar Addressing PYP and HMDP Protocols

ASNC’s upcoming Optimizing the Diagnosis of ATTR-CM Webinar will explore how to use ^99mTc-HMDP as an alternative to ^99mTc-PYP and provide the latest guidance on acquisition, interpretation, and reporting techniques. The program will also highlight the importance of SPECT and SPECT/CT imaging.

The webinar, convening March 18 from 6:00 to 7:00 PM (Eastern Time), is complimentary for ASNC members.  (Not yet a member? Join now.)

Register for Webinar